Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169668 | 0.87 | ERCC1 (0.60) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24576001 | 0.86 | MEN1 (0.63) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3556571 | 0.85 | ALDH1A1 (0.62) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13104785 | 0.85 | RAB9A (0.61) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24649296 | 0.84 | CARM1 (0.58) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5932415 | 0.83 | MEN1 (0.59) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9272879 | 0.83 | CYP2C9 (0.65) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5932406 | 0.83 | MEN1 (0.59) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13652539 | 0.81 | ALDH1A1 (0.63) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18232498 | 0.80 | ALDH1A1 (0.61) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | MEN1 1357/4885KMT2A 606/4885RAB9A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.